Navigating the Future: Non-Alcoholic Steatohepatitis Treatment Market Trends and Forecast Insights, 2025 Edition

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Non-Alcoholic Steatohepatitis Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for treatment of non-alcoholic steatohepatitis has seen a dramatic expansion in the past few years. It is set to increase from $2.6 billion in 2024 to $3.6 billion in 2025, representing a compound annual growth rate (CAGR) of 38.5%. The historic growth has been driven by an increase in the occurrence of NASH, heightened awareness and diagnosis rates, changes in lifestyle habits and the obesity crisis, advancements in clinical research, better health care infrastructure and access, favorable regulatory support and clinical trials.

How Will the Non-Alcoholic Steatohepatitis Treatment Market Size Evolve and Grow by 2029?
The market for non-alcoholic steatohepatitis treatment is projected to witness rapid expansion in the coming years, ballooning to $13.83 billion by 2029, with an impressive compound annual growth rate (CAGR) of 40.0%. The market's expected growth during the forecasted period can be tied to the enhancement of drug development protocols, a raised awareness of the disease, the increasing occurrence and risk factor, and a shift towards bespoke medicine. Key trends anticipated during this forecast period consist of a patient-oriented methodology, technological innovation, strategically tailored therapies, a changing regulatory environment, and progress in research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Drivers Are Propelling the Growth of Non-Alcoholic Steatohepatitis Treatment Market Forward?
The surge in insulin resistance cases has been a primary driver for the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance, a condition where muscle, fat, and liver cells demonstrate inadequate response to insulin, prohibiting efficient glucose absorption from the bloodstream and leading to high blood sugar levels, is directly linked to an unhealthy lifestyle, excessive sugar intake, and hereditary factors. Due to the growing numbers of diabetes and liver-related health issues, treatments targeting non-alcoholic steatohepatitis are gaining more recognition. For example, a 2022 report by the International Diabetes Federation, a diabetes community based in Belgium, stated that diabetes afflicts 537 million individuals aged 20-79 years, or one out of every ten people, with projected increases to 643 million by 2030 and 783 million by 2045. On a similar note, the American Cancer Society, a non-profit cancer advocacy organization in the US, predicted newly-diagnosed liver cancer cases to reach 41,630 in 2024, showing a rise from 41,210 in 2023. Thus, the escalating instances of insulin resistance related to various liver diseases and diabetes will continue to propel growth in the non-alcoholic steatohepatitis treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Which Emerging Trends Are Transforming the Non-Alcoholic Steatohepatitis Treatment Market in 2025?
A notable trend gaining momentum in the non-alcoholic steatohepatitis treatment marketplace is the progress in the creation of the non-alcoholic steatohepatitis (NASH) drug. Numerous businesses are focusing their efforts on the innovation of unique medications for the treatment of liver disorders, with an emphasis on reducing drug side effects. To illustrate, Pfizer Inc., a US-based pharmaceutical and biotechnology firm, secured a grant from the U.S. Food and Drug Administration (FDA) in May 2022 for the expedited development of the NASH drug, specifically ervogastat and clesacostat. The Fast Track designation provides Pfizer a streamlined process to facilitate the combined experimental therapy for non-alcoholic steatohepatitis (NASH) with liver fibrosis, named ervogastat (PF-06865571, also known as a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, classified as an acetyl-CoA carboxylase inhibitor, or ACCi).

What Are the Key Segments in the Non-Alcoholic Steatohepatitis Treatment Market?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented -

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E s, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Who Are the Key Players Shaping the Non-Alcoholic Steatohepatitis Treatment Market's Competitive Landscape?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Geographic Markets Are Powering Growth in the Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.